HLA-DRB1 haplotypes predict cardiovascular mortality in inflammatory polyarthritis independent of CRP and anti-CCP status

Seema Sharma1, Darren Plant1, John Bowes1, Alex Macgregor2,3, Suzanne Verstappen1,4, Anne Barton1,4 and Sebastien Viatte1,5*

Abstract

Background: Haplotypes defined by amino acids at HLA-DRB1 positions 11, 71 and 74 associated with susceptibility to rheumatoid arthritis (RA) are associated with radiological outcome, anti-TNF response and all-cause mortality in RA. RA is associated with cardiovascular (CV) morbidity and mortality, but the increased prevalence of risk factors of CV disease in RA only partially explains this association. The aim of this study was to investigate whether amino acids at positions 11, 71 and 74 of HLA-DRB1 are associated with cardiovascular (CV) mortality in inflammatory polyarthritis (IP).

Methods: The Norfolk Arthritis Register (NOAR) is an incidence register of IP: recruitment 1990–2007, final follow-up 2011. Two thousand five hundred fourteen patients had available genetic and mortality data. Amino acids at positions 11, 71 and 74 of HLA-DRB1 were determined. Univariate Cox proportional hazard models were applied to assess the association of genetic markers and both all-cause mortality and cardiovascular mortality.

Results: Among 2514 participants, 643 (25.6%) died during the study, and 343 (53.3%) of these deaths were attributed to CV causes. One thousand six hundred fifty (65.6%) participants were female, 709 (32.3%) were anti-CCP-positive and the median age of participants was 54.

HLA-DRB1 haplotypes associated with susceptibility to rheumatoid arthritis (RA) consistently show the same magnitude and direction of association for overall and CV mortality in IP. For example, the SEA-haplotype, associated with the lowest susceptibility to RA, and the best radiographic outcome, was found to be associated with decreased CV mortality (HR 0.67, 95% CI 0.47, 0.91, p=0.023). Mediation analysis revealed associations were independent of anti-CCP status.

Conclusions: HLA-DRB1 haplotypes associated with susceptibility to RA also predispose to increased risk of CV mortality in IP; independent of known CV risk factors. Associations were independent of anti-CCP status, which suggests in the future, genetic factors will add to the prediction of risk of cardiovascular mortality beyond serological markers.

Keywords: Cardiovascular mortality, Genetic biomarkers, HLA-DRB1, Rheumatoid arthritis, Anti-citrullinated protein antibodies

Key messages

- Positions 11, 71 and 74 of HLA-DRB1 are associated with cardiovascular mortality in inflammatory polyarthritis.
• Position 11, which has not been previously implicated with cardiovascular mortality, shows the strongest association. This effect is independent of anti-CCP status and CRP at baseline.

• The findings suggest that genetic factors may to the prediction of risk of cardiovascular mortality beyond traditional cardiovascular risk factors and serological markers.

Introduction
Rheumatoid arthritis (RA) is associated with cardiovascular (CV) morbidity and mortality [1]. Identifying those at greatest risk could have the potential to enable better risk stratification at disease onset and target interventions to those of greatest need. Traditional CV risk factors amongst patients with RA do not completely explain the risk of premature death noted in this patient group [2]. It is thought that increased inflammation may promote atherosclerosis, a notion supported by the finding that those with greater disease burden are most at risk of all-cause mortality [3, 4]. Genetic factors have also been implicated in the mechanism underlying the prevalence of CV mortality in RA [5, 6].

RA genetic susceptibility alleles at the HLA-DRB1 gene locus encoding for a conserved amino acid sequence at positions 70–74 are known as “the shared epitope” (SE). The SE alleles, have been found in previous studies to be associated with mortality in RA, a substantial component of which was through CV disease [3, 7].

Recently, amino acids at HLA-DRB1 position 11, outside the SE, were shown to be the strongest genetic predictors of RA susceptibility [8–11]. Additionally, we could show that 16 haplotypes, as defined by amino acid positions 11, 71 and 74 of HLA-DRB1, were associated with radiological outcome, anti-TNF response and all-cause mortality in RA and that these haplotypes can be ranked in a hierarchy according to risk [12]. We hypothesise that these haplotypes are also associated with CV mortality.

The aim of this study was to identify whether this genetic information could add to clinical predictors at baseline, to predict those at the highest risk of cardiovascular mortality.

Patients and methods
Cohort
The Norfolk Arthritis Register (NOAR) is a primary care-based inception cohort of patients with IP defined as a minimum of 2 swollen joints for a period of at least 4 weeks [13]. Patients were recruited in 1989 and followed up for up to 20 years. NOAR patients with at least 2 years of follow-up time with available mortality and genetic data were included in this study [6]. Ethical approval was granted by the Norwich Research Ethics committee. All patients were recruited following informed consent.

Genotyping
A semiautomated, reverse dot-blot method was used in HLA typing [14]. All samples of sufficient quality were additionally genotyped using a single-nucleotide polymorphism microarray (Illumina Infinium Immunochip) and imputed at the amino acid resolution [15]. Amino acids at positions 11, 71 and 74 were determined, combinations of which result in a total of sixteen possible haplotypes. These haplotypes have been previously grouped into four groups as defined previously [12]. Full-genotyping methodology, including nomenclature and a list of possible amino acids at DRB1 positions 11, 71, or 74, can be found elsewhere [12].

Serology
Anticyclic citrullinated peptide antibody positivity (anti-CCP2) was determined with the CCP2 assay; Axis-Shield DIASTA kit (Axis-Shield Dundee, UK), where > 5 U/ml was defined as positive.

Mortality
Data on all-cause mortality and CV mortality was provided by the Office for National Statistics, as described previously, where CV mortality was recognised as CVD mentioned on the death certification, using the International Classification of Diseases Tenth Revision [7].

Statistical analysis
Univariate Cox proportional hazard models were applied to assess the association of genetic markers and both all-cause mortality and CV mortality. Models for all-cause and CV mortality were adjusted for available CV risk factors: obesity, gender and evidence of hypertension (defined by self-reported co-prescription of antihypertensive agents). These covariates were identified using forward stepwise regression. Variables found to be collinear were not included in the final analysis. These were smoking status, evidence of diabetes (defined as self-reported co-prescription of diabetes medications), age at baseline assessment and statin use. Data on all variables was collected at baseline assessment.

Hazard models were firstly applied to the entire cohort of patients with IP and then restricted to patients who fulfilled the 1987 classification criteria for RA. When calculating differences between highest and lowest risk genetic factors, bivariate analysis was used. Results are reported as hazard ratios with 95% confidence intervals.

Lastly, a multivariate cox-proportional hazard model was applied to the 3 most frequent haplotypes occurring
in the NOAR cohort, defined by an allele frequency of over 12% to test their association with CV mortality. A one-tailed $p$ value was calculated using a linear regression model to determine the association between effect sizes ($\beta$ coefficients) of susceptibility and CV mortality. All analysis was performed using STATA/IC 14.0.

### Mediation analysis

Mediation analysis was performed to determine whether the genetic effects of CV mortality were due to intermediate parameters (anti-CCP, CRP) [16]. This analysis was performed as per principles according to Baron and Kenny. Full methods of this analysis including acyclic diagrams to represent the hypothesis are included.

### Results

Two thousand five hundred fourteen subjects in NOAR were identified to have genotype and mortality data available. Of these, 643 (25.6%) died during the study and 343 (53.3%) of these deaths were attributed to CV causes. Cohort characteristics are summarised in Table 1.

HLA-DRB1 amino acids, haplotypes, or haplotype groups associated with RA susceptibility are also associated with CV mortality and this association is independent of sex, hypertension and obesity (Table 2). HLA-DRB1 polymorphisms encoding amino-acid haplotypes associated with an increased or decreased susceptibility to RA consistently show the same magnitude and direction of association for overall and cardiovascular mortality in IP and RA [6]. For example, the SEA-haplotype, associated with the lowest susceptibility to RA, and the best radiographic outcome, was found to be associated with decreased cardiovascular mortality (HR 0.67, 95% CI 0.47 to 0.94, $p=0.023$) [6]. The relative difference in mortality between carriers of the high susceptibility VKA haplotype and carriers of the SEA haplotype was significant (HR 1.67, 95% CI 1.13 to 2.48, $p=0.01$). The analysis was repeated adjusting for anti-CCP status and associations were found to be independent of this serological marker. The association with group 4 haplotypes remained statistically significant after adjustment for anti-CCP status (HR=0.74, 95% CI 0.60 to 0.92, $p=0.007$).

HLA-DRB1 haplotypes can be ranked according to the magnitude of their association with RA susceptibility, and we have previously shown that this hierarchy is conserved for various measures of disease outcome and overall mortality [5, 8]. Our results show that this risk hierarchy is also conserved for CV mortality: HLA-DRB1 haplotypes that predispose to RA also predispose to increased CV mortality, independent of known CV risk factors (Fig. 1).

We next performed mediation analysis and the results of the step-by-step analysis are shown in Table 3. Genetic markers (serine at position 11; Ser$^{11}$) are shown to be associated with CRP ($−2.49 \pm 4.13, −0.85$, $p=0.003$) and in a separate model, with anti-CCP ($−0.85, −1.00, −0.70$, $p=0.000$). However, in a model containing both of these factors, Ser$^{11}$ is no longer associated with CRP ($p=0.614$), suggesting the association between Ser$^{11}$ and CRP is fully mediated by anti-CCP status. We found that Ser$^{11}$ is associated with cardiovascular mortality, and some of this association is independent of anti-CCP and CRP. This is demonstrated in a final model, containing Ser$^{11}$, CRP and anti-CCP, where Ser$^{11}$ remained protective (0.83 [0.69–1.00], $p=0.048$). This suggests there is a non-systemic pathway through which genetic markers may exert an effect on CV mortality. These findings are depicted in cyclic diagrams in Fig. 2.

### Discussion

It has been shown that CV mortality in RA has, in part, a genetic basis. "The shared epitope" (SE) has been previously shown to be associated with CV mortality, and this association is independent of autoantibody status [6, 7, 17]. To our knowledge, the association between amino acids at positions 11, 71 and 74 of HLA-DRB1 and CV mortality in RA has not previously been explored. We demonstrate that these originally reported genetic associations between HLA-DRB1 polymorphisms and disease susceptibility and severity are also associated with CV mortality.

Valine at position 11 of HLA-DRB1, outside of the SE, was shown to have the highest association with disease susceptibility, radiological damage and all-cause mortality, whilst serine at this position was most protective [8–12]. In this study, we demonstrate that the relative differences in CV mortality between carriers of high and low susceptibility genetic risk factors are similar to that of all-cause mortality.

There are some possible explanations behind the associations between HLA-DRB1 haplotypes and CV mortality.
Table 2  Association statistics between genetic polymorphisms located within the HLA-DRB1 gene and disease mortality

| Amino acid/haplotype/group | Inflammatory polyarthritis (IP) | Rheumatoid arthritis (RA) |
|----------------------------|---------------------------------|---------------------------|
|                            | All-cause mortality             | All-cause mortality       |
|                            | Cardiovascular mortality        | Cardiovascular mortality  |
|                            | Hazard ratio (95% CI)            | Hazard ratio (95% CI)     |
|                            | p value                          | p value                   |
|                            | n                               | n                         |
| Valine 11                  | 1.16 (1.03, 1.30)                | 1.10 (0.95, 1.28)         |
|                            | 0.015                           | 0.217                     |
|                            | 643 (2514)                      | 367 (1160)                |
| Serine 11                  | 0.83 (0.75, 0.94)                | 0.82 (0.70, 0.97)         |
|                            | 0.003                           | 0.016                     |
|                            | 643 (2514)                      | 343 (2514)                |
| Difference                 | 1.26 (1.09, 1.45)                | 1.23 (1.01, 1.49)         |
|                            | 0.001                           | 0.038                     |
|                            | 643 (2514)                      | 343 (2514)                |
| VKA haplotype              | 1.15 (0.99, 1.34)                | 1.16 (0.94, 1.43)         |
|                            | 0.073                           | 0.158                     |
|                            | 579 (2328)                      | 310 (2328)                |
| SEA haplotype              | 0.76 (0.59, 0.96)                | 0.67 (0.47, 0.94)         |
|                            | 0.024                           | 0.023                     |
|                            | 579 (2328)                      | 310 (2328)                |
| Difference                 | 1.46 (1.11, 1.93)                | 1.67 (1.13, 2.48)         |
|                            | 0.007                           | 0.010                     |
|                            | 579 (2328)                      | 310 (2328)                |
| Group 1                    | 1.11 (0.98, 1.26)                | 1.10 (0.93, 1.31)         |
|                            | 0.010                           | 0.266                     |
|                            | 579 (2328)                      | 319 (2328)                |
| Group 4                    | 0.78 (0.67, 0.90)                | 0.73 (0.60, 0.89)         |
|                            | 0.001                           | 0.002                     |
|                            | 579 (2328)                      | 319 (2328)                |
| Difference                 | 1.31 (1.11, 1.54)                | 1.37 (1.09, 1.72)         |
|                            | 0.001                           | 0.007                     |
|                            | 579 (2328)                      | 1.27 (1.02, 1.58)         |

*Group 1* and *Group 4* refer to groups of haplotypes as previously defined in a previous publication [9]. Valine at position 11, the VKA haplotype and *group 1* haplotypes have previously been shown to be associated with the highest risk of susceptibility to RA [5]. Conversely, serine at position 11, the SEA haplotype and *group 4* haplotypes have been shown to be associated with the lowest risk [9]. Results are displayed as hazard ratios (HR) with 95% confidence intervals. The total number (n) of deaths is also displayed alongside the total number (n) of patients included in each analysis (in brackets). All models have been adjusted for cardiovascular risk factors namely: gender, hypertension and obesity. HR was not adjusted for other amino acids/haplotypes/groups. "Difference": the difference in HR was calculated by the linear combination of the two HR obtained from a bivariate analysis (both amino acids/haplotypes/groups included in the same model). This represents the risk of death for the carriage of the highest risk susceptibility amino acid/haplotype/group, compared to the lowest risk amino acid/haplotype/group.
mortality in inflammatory polyarthritis patients. HLA-DRB1 haplotypes increase susceptibility to RA which in turn is well known to increase CV morbidity and mortality. However, when restricting the analysis to those who satisfied criteria for RA only, effect sizes for highest risk haplotype (VKA) and lowest risk (SEA) increase. This suggests that there is a mechanism through which HLA independently influences the risk of CV death in these patients, as opposed to solely through the development of RA.

One possible explanation of the influence of HLA-DRB1 haplotypes on this risk is through increased systemic inflammation [18]. In mediation analysis, the effect of serine at position 11 on CV mortality was partially but not completely mediated through anti-CCP status and CRP. This suggested an independent non-systemic pathway through which HLA-DRB1 haplotypes are associated with CV mortality, which is yet to be elucidated.

Another possible mechanism behind the association of HLA-DRB1 haplotypes with CV mortality may be as a result of increased disease severity rather than increased susceptibility. Those with severe disease are more likely to carry risk haplotypes as previously demonstrated [12]. If those patients are also more predisposed to CV mortality, this could also explain the results found.

The exact mechanism of action underlying the association of HLA-DRB1 haplotypes with susceptibility to and outcome of RA remains a matter of debate. However, mounting evidence suggests that haplotypes associated with high susceptibility and more severe outcomes carry amino acids within their peptide-binding groove which will increase affinity to autoantigenic peptides [19]. The presentation of autoantigenic peptides to CD4+ T and the activation of these cells are likely to play a crucial role in the onset and maintenance of the disease [20].

To our knowledge, there are no other studies looking specifically at CV mortality and HLA-DRB1 haplotypes defined by positions 11, 71 and 74. However, there is a study involving a male-predominant cohort of US veterans, which explored the association with these haplotypes and all-cause mortality [21]. Although they did not find an association with VKA and SEA haplotypes and all-cause mortality, it is possible the study was underpowered (1443 participants versus 2514 in NOAR). In addition, the NOAR participants were more likely to be female, had a lower comorbidity burden and
lower smoking prevalence and were much less likely to be on disease-modifying therapy at baseline. These factors across the two populations could also explain the differences in results for overall mortality.

A particular strength of this study is that NOAR is a large inception cohort of patients with inflammatory polyarthritis with the availability of genetic and mortality data. There are some limitations to this study: information on CV mortality was derived from death certification, which may be inaccurate. The data on covariates was collected at baseline, and it is possible that the status of these may change through the course of follow-up. However, the aim of this study was to inform the prediction of those at highest risk at disease onset, making this a greater representation of a clinical setting. Clearly, replication of these findings in independent cohorts would be required to confirm these findings and to determine the role of patients’ HLA typing in the assessment of CV risk in RA.

Treatment of RA has changed considerably since the conception of NOAR, and there is evidence that effective treatment of disease activity reduces the risk of premature cardiovascular death. Further investigation would be required to evaluate whether this also modulates the association between HLA-DRB1 haplotypes and CV mortality.

Table 3  Mediation analysis

The results of mediation analysis which was performed as per principles according to Baron and Kennedy. This was performed in steps as shown in order to determine whether the association of the above genetic factors with CV mortality was likely to be through intermediate parameters of inflammation. Proposed pathways are summarised in Fig. 2.

| Step 1: Association of serine at position 11 and mediators |
|-----------------------------------------------------------|
| Model | Variable | B coefficient | p value | Interpretation |
| Linear regression: serine 11, CRP | CRP | $-2.49$ ($-4.13,-0.85$) | 0.003 | Suggests serine 11 is associated with CRP |
| Logistic regression: serine 11, anti-CCP | Anti-CCP | $-0.85$ ($-1.00,-0.70$) | 0.000 | Suggests serine 11 is associated with anti-CCP status |
| Multivariate regression: serine 11, anti-CCP and CRP | CRP | $0.00$ (0.00, 0.00) | 0.614 | Suggests association between serine 11 and CRP fully mediated by ACPA status. |
| | Anti-CCP | $-0.37$ ($-0.43,-0.30$) | 0.000 |

| Step 2: Association of serine at position 11 and cardiovascular mortality |
|---------------------------------------------------------------|
| Model | Variable | Hazard ratio | p value | Interpretation |
| Model predicting CV mortality (controlled for cv risk factors) with serine 11 | Serine 11 | 0.82 (0.70, 0.96) | 0.016 | Suggests association between serine 11 and CV mortality |

| Step 3: Association of Serine at position 11 and cardiovascular mortality |
|---------------------------------------------------------------|
| Model | Variable | Hazard ratio | p value | Interpretation |
| Model predicting CV mortality (controlled for cv risk factors) with serine 11, CRP | CRP | 1.01 (1.00, 1.01) | 0.001 | Suggests association of CRP and CV mortality |
| | Serine 11 | 0.83 (0.70, 0.99) | 0.034 | Suggests association of serine 11 and CV mortality, independent of CRP |
| Model predicting CV mortality (controlled for cv risk factors) with serine 11, ACPA | Anti-CCP | 1.50 (1.18, 1.92) | 0.001 | Suggests association of anti-CCP and CV mortality |
| | Serine 11 | 0.81 (0.68, 0.98) | 0.027 | Suggests association of serine 11 and CV mortality, independent of anti-CCP |
| Model predicting CV mortality (controlled for cv risk factors) with serine 11, ACPA, CRP | CRP | 1.00 (1.00, 1.01) | 0.005 | Suggests association of CRP and CV mortality, independent of anti-CCP |
| | Anti-CCP | 1.40 (1.08, 1.81) | 0.011 | Suggests association of anti-CCP and CV mortality |
| | Serine 11 | 0.83 (0.69, 1.00) | 0.048 | Suggests association of serine 11 and CV mortality, independent of anti-CCP and CRP |

| Other relevant models |
|-----------------------|
| Model | Variable | B coefficient | p value |
| Regression CRP, anti-CCP | Anti-CCP | 12.71 (10.55, 14.87) | 0.000 |

Association of serine at position 11 and rheumatoid factor was also tested which showed a significant association. However, when adjusted for anti-CCP, this association no longer stood. For this reason, the rheumatoid factor was not included in further mediation analysis. See below:

| Model | Variable | B coefficient | p value |
| Regression model serine 11, rheumatoid factor and anti-CCP | Anti-CCP | $-0.35$ ($-0.42, -0.28$) | 0.000 |
| Rheumatoid factor | $-0.01$ ($-0.09, 0.06$) | 0.691 |

Conclusions
CV disease and mortality remain a significant challenge in the management of RA. Understanding the mechanisms underpinning genetic associations of mortality in
RA could help enable risk stratification of patients from disease presentation. Our findings show HLA-DRB1 haplotypes associated with susceptibility to RA also predispose to increased risk of CV mortality in IP, independent of known CV risk factors. Notably, associations were persistent after adjustment of anti-CCP status. This suggests in the future that genetic factors will add to the prediction of the risk of cardiovascular mortality beyond serological markers. The clinical utility of whether HLA typing in informing management of cardiovascular risk remains to be explored, but would likely form part of a larger tool including clinical and serological predictors.

**Abbreviations**
RA: Rheumatoid arthritis; IP: Inflammatory polyarthritis; CVD: Cardiovascular disease; CV: Cardiovascular; CRP: C-reactive protein; SE: Shared epitope; CI: Confidence interval; CCP: Anti-cyclic citrullinated peptide; HLA: Human leukocyte antigen; NOAR: Norfolk Arthritis Register; Ser11: Serine at position 11.

**Acknowledgements**
The authors would like to thank the patients involved in NOAR and all supporting staff involved in its implementation. The authors also thank Professor Deborah Symmons for her involvement in the inception of the NOAR cohort.

**Role of funders/sponsors**
The funders had no role in the design and conduct of the study; collection, management, analysis and interpretation of the data; preparation, review or approval of the manuscript; and decision to submit the manuscript for publication.

**Patient and public involvement statement**
The research user group (RUG) at the centre for musculoskeletal research is a patient-partner initiative supported by the Manchester University, NHRI and Versus Arthritis. They give regular input regarding the design and management of research and dissemination of study results.

**Transparency declaration**
I (Seema Sharma, the lead author and manuscript’s guarantor) affirm that the manuscript is an honest, accurate and transparent account of the study being reported; that no important aspects of the study have been omitted and that any discrepancies from the study as planned (and, if relevant, registered) have been explained.

**Authors’ contributions**
Dr. Sharma had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Study concept and design: SV, AB, SZV, AM. Acquisition, analysis or interpretation of data: SS, SV, DP, JB. Drafting of the manuscript: SV, SS. Critical revision of the manuscript for important intellectual content: AB, AM, JB, DP, SV. Statistical analysis: SV, SS. Obtained funding: AB, JB, SS, SV. Administrative, technical, or material support: AB, JB, DP, AM, SZV. Study supervision: SV, AB. All authors gave their final approval for this manuscript to be published and agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. The authors read and approved the final manuscript.

**Funding**
Dr. Sharma was supported by the NHRI through an ACF post as part of the integrated academic training (IAT) programme. Dr. Bowes would like to acknowledge grant 34765 (BHF). The authors would like to acknowledge the core programme grant by Versus Arthritis.

**Availability of data and materials**
The data that support the findings of this study are available from the corresponding author, [SV], upon request, wherever legally and ethically possible.

**Declarations**

**Ethics approval and consent to participate**
Ethical approval to perform genetic association studies in NOAR - REC Ref 2003/075, 18 December 2003, Norwich Local Research Committee (NHS).

**Competing interests**
All authors have completed the Unified Competing Interest Form (available on request from the corresponding author) and declare no support from any organisation for the submitted work, no financial relationships with any organisations that might have an interest in the submitted work in the previous 3 years, and no other relationships or activities that could appear to have influenced the submitted work. Dr. Barton reported receiving speaker fees from Roche Chugai and grant support from BMS. Dr. Bowes reported a project grant from BHF.

**Author details**

1Centre for Genetics and Genomics Versus Arthritis, Centre for Musculoskeletal Research, Manchester Academic Health Science Centre, The University...
Received: 11 November 2021 Accepted: 18 March 2022
Published online: 25 April 2022

References
1. Wallberg-Jonsson S, Ohman ML, Dahlqvist SR. Cardiovascular morbidity and mortality in patients with seropositive rheumatoid arthritis in northern Sweden. J Rheumatol. 1997;24(3):445–51.
2. del Rincón ID, et al. High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors. Arthritis Rheum. 2001;44(12):2737–45.
3. Goodson NJ, et al. Baseline levels of C-reactive protein and prediction of death from cardiovascular disease in patients with inflammatory polyarthritis: a ten-year followup study of a primary care-based inception cohort. Arthritis Rheum. 2005;52(8):2293–9.
4. Wallberg-Jonsson S, et al. Extent of inflammation predicts cardiovascular disease and overall mortality in seropositive rheumatoid arthritis: A retrospective cohort study from disease onset. J Rheumatol. 1999;26(12):2562–71.
5. Gonzalez-Juanatey C, et al. HLA-DRB1 status affects endothelial function in treated patients with rheumatoid arthritis. Am J Med. 2003;114(8):647–52.
6. Gonzalez-Gay MA, et al. HLA-DRB1 and persistent chronic inflammation contribute to cardiovascular events and cardiovascular mortality in patients with rheumatoid arthritis. Arthritis Care Res. 2007;57(1):125–32.
7. Faragher TM, et al. Association of the HLA-DRB1 gene with premature death, particularly from cardiovascular disease, in patients with rheumatoid arthritis and inflammatory polyarthritis. Arthritis Rheum. 2008;58(2):359–69.
8. Raychaudhuri S, et al. Five amino acids in three HLA proteins explain most of the association between MHC and seropositive rheumatoid arthritis. Nat Genet. 2012;44(3):291–6.
9. Han B, et al. Fine mapping seronegative and seropositive rheumatoid arthritis to shared and distinct HLA alleles by adjusting for the effects of heterogeneity. Am J Hum Genet. 2014;94(4):522–32.
10. Tan LK, et al. The spectrum of association in HLA region with rheumatoid arthritis in a diverse Asian population: evidence from the MyERA case-control study. Arthritis Res Ther. 2021;23(1):46.
11. Govind N, et al. HLA-DRB1 amino acid positions and residues associated with antibody-positive rheumatoid arthritis in black south Africans. J Rheumatol. 2019;46(2):138–44.
12. Viatte S, et al. Association of HLA-DRB1 haplotypes with rheumatoid arthritis severity, mortality, and treatment response. JAMA. 2015;313(16):1645–56.
13. Symmons DP, Silman AJ. The Norwich arthritis register (NOAR). Clin Exp Rheumatol. 2003;21(Suppl 31):S94–9.
14. Thomson W, et al. Quantifying the exact role of HLA-DRB1 alleles in susceptibility to inflammatory polyarthritis: results from a large, population-based study. Arthritis Rheum. 1999;42(4):757–62.
15. Eyre S, et al. High-density genetic mapping identifies new susceptibility loci for rheumatoid arthritis. Nat Genet. 2012;44(12):1336–40.
16. The moderator–mediator variable distinction in social psychological research: conceptual, strategic, and statistical considerations. 1986, American Psychological Association: US. p. 1173–1182.
17. Matthey DL, et al. Association of DRB1 shared epitope genotypes with early mortality in rheumatoid arthritis: results of eighteen years of followup from the early rheumatoid arthritis study. Arthritis Rheum. 2007;56(5):1408–16.
18. Ling SF, et al. HLA–DRB1 amino acid positions 11/13, 71, and 74 are associated with inflammation level, disease activity, and the health assessment questionnaire score in patients with inflammatory polyarthritis. Arthritis Rheum. 2016;68(11):2618–28.
19. Viatte S, Plant D, Raychaudhuri S. Genetics and epigenetics of rheumatoid arthritis. Nat Rev Rheumatol. 2013;9(3):141–53.
20. James EA, et al. Citrulline-specific T Helper cells are increased in rheumatoid arthritis. Arthritis Rheum. 2014;66(7):1712–22.
21. Zhao M, et al. HLA-DRB1 haplotypes, shared epitope, and disease outcomes in US veterans with rheumatoid arthritis. J Rheumatol. 2019;46(7):685–93.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.